Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Angion Biomedica Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ELTX
Nasdaq
8731
https://elicio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Angion Biomedica Corp
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
- Apr 25th, 2024 12:30 pm
Robert Connelly Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) CEO is the most bullish insider, and their stock value gained 11%last week
- Apr 13th, 2024 1:19 pm
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
- Apr 5th, 2024 8:30 pm
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
- Mar 29th, 2024 12:30 pm
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
- Mar 18th, 2024 12:00 pm
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
- Mar 6th, 2024 1:30 pm
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 5th, 2024 1:30 pm
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
- Jan 25th, 2024 2:00 pm
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
- Jan 17th, 2024 1:30 pm
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
- Jan 16th, 2024 1:30 pm
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
- Jan 11th, 2024 1:30 pm
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
- Jan 9th, 2024 11:00 am
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
- Dec 22nd, 2023 2:00 pm
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Dec 4th, 2023 1:00 pm
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Nov 9th, 2023 9:30 pm
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
- Nov 3rd, 2023 8:30 pm
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
- Oct 11th, 2023 12:00 pm
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
- Sep 27th, 2023 9:30 pm
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
- Sep 7th, 2023 12:00 pm
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 12:00 pm
Scroll